Sugi Predict

Sugi Predict / Compounds / SCHEMBL2188781

SCHEMBL2188781

SCHEMBL2188781

O=C(CCCCCNC(=O)OCc1ccccc1)CC1CN[C@@H](C(=O)N2CCC(c3ccccc3)C2)[C@@H](C(=O)O)C1

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ADAM10 O14672 11/20 0.76
▸ ERBB2 P04626 11/20 0.76
▸ MMP2 P08253 10/20 0.76
▸ MMP3 P08254 1/20 0.76
▸ MMP9 P14780 1/20 0.76
▸ F13A1 P00488 1/20 0.43
▸ TGM2 P21980 1/20 0.43
▸ TGM1 P22735 1/20 0.43
▸ PREP P48147 2/20 0.43
▸ TPSAB1 Q15661 2/20 0.41
▸ TPSD1 Q9BZJ3 2/20 0.41
▸ TPSG1 Q9NRR2 2/20 0.41
▸ DPP4 P27487 2/20 0.39
▸ DPP8 Q6V1X1 2/20 0.39
▸ DPP9 Q86TI2 2/20 0.39
▸ DPP7 Q9UHL4 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2188772 1.00 ADAM10 (0.76) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2188792 1.00 ADAM10 (0.76) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2172445 0.93 ADAM10 (0.88) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2175263 0.84 ADAM10 (0.80) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL3458109 0.83 ADAM10 (0.67) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL3462524 0.80 ADAM10 (0.55) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL3462525 0.80 ADAM10 (0.55) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL3457440 0.78 ADAM10 (0.67) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2173649 0.78 ADAM10 (0.80) ADAM10ERBB2MMP2MMP3MMP9
SCHEMBL2175380 0.77 ADAM10 (0.66) ADAM10ERBB2MMP2MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 — — US disclosed
US-20150025056-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION (US) 2015-01-22 — — US disclosed
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 — — US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 — — US disclosed
EP-2264030-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases Incyte Corporation (US) 2010-12-22 — — EP disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 — — US disclosed
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases LNCYTE CORPORATION (US) 2008-07-10 — — US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 ADAM10 25/4885ERBB2 2986/4885MMP2 4/4885
US-20150025056-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP2, MMP14 ADAM10 26/4885ERBB2 3036/4885MMP2 2/4885
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases MMP25, MMP9, MMP24 ADAM10 25/4885ERBB2 3033/4885MMP2 5/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 ADAM10 26/4885ERBB2 3036/4885MMP2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.